Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Monday, Wall Street Zen reports.
A number of other equities analysts have also recently commented on the company. Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a research note on Thursday, September 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 15th. Oppenheimer reissued an "outperform" rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, October 20th. Royal Bank Of Canada began coverage on Eupraxia Pharmaceuticals in a report on Monday, November 9th. They set an "outperform" rating and a $14.00 price target for the company. Finally, HC Wainwright lifted their target price on Eupraxia Pharmaceuticals from $11.00 to $16.00 and gave the stock a "buy" rating in a report on Wednesday, November 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.
View Our Latest Research Report on Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Price Performance
EPRX opened at $8.15 on Monday. The company has a quick ratio of 12.25, a current ratio of 12.25 and a debt-to-equity ratio of 0.03. The stock has a market cap of $548.02 million, a PE ratio of -7.69 and a beta of 1.04. The business's fifty day simple moving average is $7.64 and its 200 day simple moving average is $7.24. Eupraxia Pharmaceuticals has a 52 week low of $5.63 and a 52 week high of $9.32.
Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.03. As a group, research analysts expect that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.
Institutional Trading of Eupraxia Pharmaceuticals
Institutional investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP purchased a new position in Eupraxia Pharmaceuticals during the first quarter valued at $5,137,000. Redmile Group LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 1st quarter valued at approximately $5,068,000. Rubric Capital Management LP bought a new stake in Eupraxia Pharmaceuticals in the first quarter worth $5,004,000. Cibc World Market Inc. purchased a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth about $1,539,000. Finally, Bank of America Corp DE bought a new position in shares of Eupraxia Pharmaceuticals during the second quarter valued at approximately $1,750,000.
Eupraxia Pharmaceuticals News Summary
Investors following EPRX have been watching these news items:
- Positive Sentiment: HC Wainwright kept its Buy rating and $16 price target, raising its estimates for fiscal 2026 and 2028 and moving its 2030 forecast from a loss to a profit. HC Wainwright estimate updates
- Neutral Sentiment: Interim results from Eupraxia’s Phase 2b eosinophilic esophagitis (EoE) trial are expected in December, creating a key upcoming clinical catalyst. Q3 results and trial update timing
- Negative Sentiment: HC Wainwright lowered its fiscal 2027 and 2029 EPS forecasts, while the company reported a wider third-quarter loss—risks that temper the positive analyst news. Analyst estimates Quarterly loss report
About Eupraxia Pharmaceuticals
(
Get Free Report)
Eupraxia Pharmaceuticals is a clinical-stage biotechnology company developing treatments that use its DiffuSphere drug-delivery technology. The polymer-based platform is designed to release medicines over an extended period and deliver them locally to targeted tissues. The company's lead candidate, EP-104IAR, is an extended-release formulation of fluticasone propionate being developed as an injection into the knee for people with osteoarthritis. Eupraxia is also exploring applications of its delivery platform in other conditions, including eosinophilic esophagitis.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eupraxia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eupraxia Pharmaceuticals wasn't on the list.
While Eupraxia Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.